Choroidal Response to Intravitreal Bevacizumab Injections in Treatment-Naïve Macular Neovascularization Secondary to Chronic Central Serous Chorioretinopathy

Purpose: To evaluate the impact of intravitreal bevacizumab (IVB) therapy on anatomical and visual outcomes in patients with macular neovascularization (MNV) secondary to chronic cen-tral serous chorioretinopathy (cCSC). Methods: This retrospective observational study reviewed the medical records of treatment-naïve patients diagnosed with cCSC complicated by MNV, treated with IVB injections over a 5-year period. The presence of MNV was confirmed using op-tical coherence tomography angiography (OCTA). Best-corrected visual acuity (BCVA), subfoveal choroidal thickness (SFCT), and subretinal fluid (SRF) were recorded pre- and post-IVB treat-ment. Results: Twenty-two eyes of 22 patients (mean age, 68 ± 11 years) were included. After a mean follow-up of 21.0 ± 14.6 months, SRF significantly decreased from baseline (176.86 ± 115.62 µm) to the final follow-up (80.95 ± 87.32 µm, P = 0.003). Greater SRF reduction was associated with more injections (>7) (P = 0.047). However, no significant changes were observed in BCVA (P > 0.05) or SFCT (P > 0.05), irrespective of follow-up duration or injection frequency. Complete res-olution of SRF was achieved in 9 patients (40.9%), and a significantly greater reduction in SFCT was observed in complete responders compared to non-responders (P = 0.03). Conclusion: IVB therapy significantly reduced SRF in cCSC patients with secondary MNV, though it did not lead to visual improvement or significant changes in SFCT. However, greater choroidal thinning in patients with complete fluid resorption may suggest distinct underlying mechanisms or alterna-tive sources of subretinal fluid beyond the MNV itself.